



Market Announcement

4 June 2019

Visioneering Technologies, Inc. (ASX: VTI) – Trading Halt

Description

The securities of Visioneering Technologies, Inc. ('VTI') will be placed in trading halt at the request of VTI, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 6 June 2019 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance (Sydney)



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

4 June 2019

Lisa Bahn
Senior Adviser, Listings Compliance (Sydney)
20 Bridge Street
Sydney NSW 2000

By email only: Lisa.Bahn@asx.com.au; tradinghaltssydney@asx.com.au

Dear Lisa

REQUEST FOR TRADING HALT

Visioneering Technologies Inc. (ASX: **VTI**) (**the Company**) requests an immediate halt to the trading of the Company's ordinary shares quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement to be made by the Company to the market in connection with a proposed transaction and capital raising.

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to a proposed transaction and capital raising.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Thursday 6 June 2019, or when the announcement regarding the proposed transaction and capital raising is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Thursday 6 June 2019.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely

Julian Rockett
Company Secretary
Visioneering Technologies Inc.



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. NaturalVue lenses were cleared by the FDA in late 2014 for the correction of refractive errors and VTI commenced a pilot US market launch of NaturalVue MF contact lenses from 2015 that gave way to a broader US launch in 2016 and 2017. VTI sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.